Earnings summaries and quarterly performance for Aurinia Pharmaceuticals.
Executive leadership at Aurinia Pharmaceuticals.
Board of directors at Aurinia Pharmaceuticals.
Research analysts who have asked questions during Aurinia Pharmaceuticals earnings calls.
Will Soghikian
Leerink Partners
5 questions for AUPH
Douglas Miehm
RBC Capital Markets
4 questions for AUPH
James Vane-Tempest
Jefferies Financial Group Inc.
4 questions for AUPH
Vishwesh Shah
TD Cowen
4 questions for AUPH
Olivia Brayer
Cantor
3 questions for AUPH
Yu He (Arthur)
H.C. Wainwright & Co., LLC
3 questions for AUPH
Joseph Schwartz
Oppenheimer
2 questions for AUPH
Maurice Raycroft
Jefferies Financial Group
2 questions for AUPH
Stacy Ku
TD Cowen
2 questions for AUPH
Arthur He
H.C. Wainwright & Co.
1 question for AUPH
David Martin
Bloom Burton & Co.
1 question for AUPH
Ed Arce
WestPark Capital
1 question for AUPH
Farzin Haque
Jefferies
1 question for AUPH
Sahil Dhingra
RBC Capital Markets
1 question for AUPH
Recent press releases and 8-K filings for AUPH.
- Aurinia Pharmaceuticals reported Q3 2025 total revenue of $73.5 million, an 8% increase from Q3 2024, and LUPKYNIS net product sales of $70.6 million, up 27% year-over-year.
- The company raised its 2025 total revenue guidance to $275 million-$280 million and LUPKYNIS sales guidance to $265 million-$270 million for the second time this year.
- Net income for Q3 2025 increased by 119% to $31.6 million, with diluted EPS rising 130% to $0.23.
- Aurinia is advancing its Atenercept program into clinical studies for two autoimmune diseases by the end of 2025, following positive Phase 1 results.
- For the nine months ended September 30, 2025, the company repurchased $98.2 million in shares, reducing diluted shares outstanding from 149.8 million to 138.2 million.
- Aurinia Pharmaceuticals reported Q3 2025 total revenue of $73.5 million, an 8% increase from Q3 2024, driven by LUPKYNIS net product sales of $70.6 million, up 27%.
- Net income for Q3 2025 surged 119% to $31.6 million, resulting in diluted earnings per share of $0.23, a 130% increase year-over-year.
- The company raised its full-year 2025 total revenue guidance to a range of $275 million to $280 million and net product sales guidance to $265 million to $270 million.
- As of September 30, 2025, Aurinia maintained a strong cash position with $351.8 million in cash, cash equivalents, restricted cash, and investments.
- Aurinia repurchased 12.2 million common shares for $98.2 million during the nine months ended September 30, 2025, and is advancing aritinercept towards clinical studies in two autoimmune diseases by year-end.
- Aurinia Pharmaceuticals reported net income of $31.6 million for the third quarter of 2025, a 119% increase year-over-year, and $76.4 million for the nine months ended September 30, 2025, a 1677% increase.
- Total revenue for Q3 2025 was $73.5 million and $205.9 million for the nine months, with LUPKYNIS net product sales growing 27% to $70.6 million in Q3 2025.
- The company raised its full-year 2025 guidance, projecting total revenue between $275 million and $280 million and net product sales between $265 million and $270 million.
- As of September 30, 2025, Aurinia held $351.8 million in cash, cash equivalents, restricted cash, and investments, and repurchased 12.2 million common shares for $98.2 million during the first nine months of 2025.
Quarterly earnings call transcripts for Aurinia Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track Aurinia Pharmaceuticals's earnings for you
Get instant analysis when filings drop